Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
130 participants
INTERVENTIONAL
2020-09-30
2021-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparing Tranexamic Acid Versus Ecbolics in Preventing Hemorrhage During and After Cesarean Section
NCT06060327
Comparative Study Between Oxytocin Versus Tranexamic Acid and Ethamsylate
NCT04656067
Comparison Study of Oxytocin Versus Tranexamic Acid and Etamsylaye Versus Placebo(Saline)
NCT05273632
Comparing Intramyometrial Tranexamic Acid and Oxytocin for Blood Loss in Cesarean Section
NCT06010368
Oxytocin to Decrease Blood Loss During Cesarean Section
NCT00891150
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
group A
will receive oxytocin
Oxytocin
Oxytocin
group B
will receive tranexamic acid plus oxytocin
Tranexamic acid
comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tranexamic acid
comparison between effect of oxytocin alone and tranexamic acid and oxytocin in reducing blood loss after CS
Oxytocin
Oxytocin
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 2- Gestational age is between 37-41weeks
3- Delivery by uncomplicated elective CS
Exclusion Criteria
20 Years
40 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ain Shams University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noha Mahmoud Abu Shata
egypt
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
blood loss after CS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.